论文部分内容阅读
目的:探讨分析应用曲美他嗪联合阿托伐他汀治疗不稳定性心绞痛的临床疗效。方法:选取2010年10月～2012年9月间我科收治的不稳定性心绞痛患者118例作为研究对象,将其随机分为对照组(59例)和观察组(59例)。对59例对照组患者在进行心内科常规治疗的基础上应用阿托伐他汀进行治疗,对59例观察组患者在进行常规治疗的基础上应用曲美他嗪联合阿托伐他汀进行治疗。经过一段时间的治疗,将两组患者的临床疗效、治疗的总有效率及TC、TG、LDL-C、HDL-C水平进行统计和比较,并将比较结果及两组患者的临床资料进行回顾性的分析。结果:经过一段时间的治疗,观察组患者的临床疗效明显优于对照组患者,差异显著(P<0.05),具有统计学意义。观察组患者治疗的总有效率为93.22%,对照组患者治疗的总有效率为79.66%,差异显著(P<0.05),具有统计学意义。观察组患者在治疗后的TC、TG、LDL-C、HDL-C水平明显优于治疗前,差异显著(P<0.05),具有统计学意义。对照组患者在治疗后的TC、TG、LDL-C、HDL-C水平明显优于治疗前,差异显著(P<0.05),具有统计学意义。将两组患者治疗前后的TC、TG、LDL-C、HDL-C水平进行组间比较,差异不明显(P>0.05),不具有统计学意义。结论:应用曲美他嗪联合阿托伐他汀治疗不稳定性心绞痛的临床疗效显著,治疗的总有效率明显优于单独使用阿托伐他汀,值得在临床上推广应用。
Objective: To investigate the clinical efficacy of trimetazidine combined with atorvastatin in the treatment of unstable angina pectoris. Methods: A total of 118 patients with unstable angina who were admitted to our department from October 2010 to September 2012 were selected as the research object. They were randomly divided into control group (59 cases) and observation group (59 cases). 59 patients in the control group were treated with atorvastatin on the basis of routine cardiological treatment. 59 patients in the observation group were treated with trimetazidine and atorvastatin on the basis of routine treatment. After a period of treatment, the clinical efficacy, the total effective rate of treatment and levels of TC, TG, LDL-C and HDL-C in both groups were statistically compared and compared, and the results of the comparison and the clinical data of two groups of patients were reviewed Sexual analysis. Results: After a period of treatment, the clinical efficacy of the observation group was significantly better than that of the control group (P <0.05), which was statistically significant. The total effective rate was 93.22% in the observation group and 79.66% in the control group. The difference was significant (P <0.05), with statistical significance. The levels of TC, TG, LDL-C and HDL-C in the observation group were significantly better than those before treatment (P <0.05), which were statistically significant. The levels of TC, TG, LDL-C and HDL-C in the control group were significantly better than those before treatment (P <0.05), which were statistically significant. The levels of TC, TG, LDL-C and HDL-C in the two groups before and after treatment were not significantly different between the two groups (P> 0.05), and were not statistically significant. Conclusion: The clinical efficacy of trimetazidine combined with atorvastatin in treatment of unstable angina pectoris is remarkable. The total effective rate of treatment is obviously superior to that of atorvastatin alone, which is worth popularizing in clinic.